Cargando…
Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis
Introduction: Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment or structural lung disease to cause clinical disease. Fatal cavitary infection in a patient without immunosuppression is rarely presented. Case report: A 62-year-old female with hi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738639/ https://www.ncbi.nlm.nih.gov/pubmed/29296252 http://dx.doi.org/10.1080/20009666.2017.1407211 |
_version_ | 1783287735933468672 |
---|---|
author | Abdulfattah, Omar Salhan, Divya Kandel, Saroj Rahman, Ebad Ur Dahal, Sumit Alnafoosi, Zainab Schmidt, Frances |
author_facet | Abdulfattah, Omar Salhan, Divya Kandel, Saroj Rahman, Ebad Ur Dahal, Sumit Alnafoosi, Zainab Schmidt, Frances |
author_sort | Abdulfattah, Omar |
collection | PubMed |
description | Introduction: Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment or structural lung disease to cause clinical disease. Fatal cavitary infection in a patient without immunosuppression is rarely presented. Case report: A 62-year-old female with history of sarcoidosis and hypertension presented with cough, fever and dyspnea for one week. Chest imaging showed irregular opacification of upper lung zones. The sputum samples tested positive for acid-fast bacilli (AFB) and the subsequent testing identified M. xenopi. She was started on rifampin, isoniazid, pyrazinamide and ethambutol along with azithromycin, and was discharged with plans to continue the same. A follow up sputum test was negative for AFB. She was, however, readmitted ten months later with sepsis due to pneumonia. Chest imaging revealed worsening cavitary lung lesions. Despite starting her on intravenous antibiotics while continuing anti-tubercular therapy, she developed severe respiratory distress and had to be intubated. Her condition continued to deteriorate and she expired the following day. Conclusion: Fatal cavitary infections with M. xenopi have been reported in the absence of established optimal management. Well-designed studies with sufficient power are needed to establish new treatment guidelines. |
format | Online Article Text |
id | pubmed-5738639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-57386392018-01-02 Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis Abdulfattah, Omar Salhan, Divya Kandel, Saroj Rahman, Ebad Ur Dahal, Sumit Alnafoosi, Zainab Schmidt, Frances J Community Hosp Intern Med Perspect Case Report Introduction: Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment or structural lung disease to cause clinical disease. Fatal cavitary infection in a patient without immunosuppression is rarely presented. Case report: A 62-year-old female with history of sarcoidosis and hypertension presented with cough, fever and dyspnea for one week. Chest imaging showed irregular opacification of upper lung zones. The sputum samples tested positive for acid-fast bacilli (AFB) and the subsequent testing identified M. xenopi. She was started on rifampin, isoniazid, pyrazinamide and ethambutol along with azithromycin, and was discharged with plans to continue the same. A follow up sputum test was negative for AFB. She was, however, readmitted ten months later with sepsis due to pneumonia. Chest imaging revealed worsening cavitary lung lesions. Despite starting her on intravenous antibiotics while continuing anti-tubercular therapy, she developed severe respiratory distress and had to be intubated. Her condition continued to deteriorate and she expired the following day. Conclusion: Fatal cavitary infections with M. xenopi have been reported in the absence of established optimal management. Well-designed studies with sufficient power are needed to establish new treatment guidelines. Taylor & Francis 2017-12-14 /pmc/articles/PMC5738639/ /pubmed/29296252 http://dx.doi.org/10.1080/20009666.2017.1407211 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Abdulfattah, Omar Salhan, Divya Kandel, Saroj Rahman, Ebad Ur Dahal, Sumit Alnafoosi, Zainab Schmidt, Frances Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis |
title | Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis |
title_full | Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis |
title_fullStr | Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis |
title_full_unstemmed | Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis |
title_short | Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis |
title_sort | fatal pulmonary cavitary disease secondary to mycobacterium xenopi in a patient with sarcoidosis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738639/ https://www.ncbi.nlm.nih.gov/pubmed/29296252 http://dx.doi.org/10.1080/20009666.2017.1407211 |
work_keys_str_mv | AT abdulfattahomar fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis AT salhandivya fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis AT kandelsaroj fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis AT rahmanebadur fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis AT dahalsumit fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis AT alnafoosizainab fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis AT schmidtfrances fatalpulmonarycavitarydiseasesecondarytomycobacteriumxenopiinapatientwithsarcoidosis |